Keyword: Severin Schwan

Roche CEO Schwan sees his 2019 pay dip by 2%

Thursday, March 12, 2020

Roche CEO Schwan's pay is now more closely tied to his ability to steer the company's newer drugs into blockbuster territory.

Big Pharma CEOs' Chinese names: What they mean

by Angus Liu

Tuesday, October 1, 2019

Big Pharma CEOs have their own way of cozying up to the world’s second largest pharmaceutical market—by getting themselves Chinese names.

Could FTC scrutiny of Roche-Spark merger scuttle future pharma deals?

by Arlene Weintraub

Friday, August 2, 2019

The FTC's tough stance has analysts worried that regulatory red tape could tie up AbbVie’s $63 billion purchase of Allergan and other deals.

Roche extends $4.3B Spark bid yet again, this time to September

by Angus Liu

Wednesday, July 31, 2019

You might have lost count of how many times Roche has extended the tender offer period for shares of Spark Therapeutics. As of Wednesday, it's five.

The top 20 highest-paid biopharma CEOs of 2018

by Eric Sagonowsky

As spring rolls on each year, proxy filings pile up, disclosing executive pay for the prior year. And as in past years, FiercePharma has tracked the info to present the top CEO pay packages in biopharma, ranging from nearly $60 million in 2018 down to $16 million.

18. Avastin

by Kyle Blankenship

18. Avastin

Roche's drugs, new and old, team up for major sales

by Angus Liu

Wednesday, April 17, 2019

Last July, Roche put a halt on U.S. price hikes. But that didn't stop five of its products from topping analysts' estimates by double digits in Q1.

2. Roche

by Angus Liu

Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.

Roche looks at weaker 2019 on biosim attack

by Angus Liu

Thursday, January 31, 2019

Roche expects 2019 sales growth in low- to mid-single digits, compared with 7% in 2018, partially on expected U.S. biosimilar launches.

Roche's Genentech laying off 223 staffers in California

by Eric Sagonowsky

Wednesday, August 15, 2018

With biosimilar versions of its top drugs on the horizon, Roche's Genentech unit is parting ways with 223 staffers in California.